Aortic stenosis cost-effectiveness of therapy: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
m (Bot: Adding CME Category::Cardiology) |
||
| Line 13: | Line 13: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[CME Category::Cardiology]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
| Line 21: | Line 25: | ||
[[Category:Surgery]] | [[Category:Surgery]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Revision as of 23:10, 14 March 2016
 |
Resident Survival Guide |
|
Aortic Stenosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Percutaneous Aortic Balloon Valvotomy (PABV) or Aortic Valvuloplasty |
|
Transcatheter Aortic Valve Replacement (TAVR) |
|
Case Studies |
|
Aortic stenosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Aortic stenosis cost-effectiveness of therapy |
|
Directions to Hospitals Treating Aortic stenosis cost-effectiveness of therapy |
|
Risk calculators and risk factors for Aortic stenosis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Transcatheter aortic valve implantation (TAVI) is more cost-effective compared to medical management among aortic stenosis patients unsuitable for surgery. Among patients suitable for surgery, surgical aortic valve replacement is more cost-effective than TAVI.[1]
References
- ↑ Orlando R, Pennant M, Rooney S, Khogali S, Bayliss S, Hassan A; et al. (2013). "Cost-effectiveness of transcatheter aortic valve implantation (TAVI) for aortic stenosis in patients who are high risk or contraindicated for surgery: a model-based economic evaluation". Health Technol Assess. 17 (33): 1–86. doi:10.3310/hta17330. PMID 23948359.